Inflammatory biomarkers in assessing severity and prognosis of immune checkpoint inhibitor‐associated cardiotoxicity

Inflammatory biomarkers in assessing severity and prognosis of immune checkpoint inhibitor‐associated cardiotoxicity

Abstract Aims Inflammatory biomarkers, including CRP, the neutrophil‐to‐lymphocyte ratio (NLR), and the neutrophil‐to‐eosinophil ratio (NER), may predict outcomes in cancer. However, their value in immune checkpoint inhibitor (ICI) therapy‐associated cardiotoxicity remains elusive. We aimed to chara...

Full description

Bibliographic Details
Main Authors:	Lin Liang, Chanjuan Cui, Dan Lv, Yiqun Li, Liyan Huang, Jiayu Feng, Tao An, Pengchao Tian, Ke Yang, Linjun Hu, Lizhen Gao, Jian Zhang, Yuhui Zhang, Fei Ma, Yanfeng Wang
Format:	Article
Language:	English
Published:	Wiley 2023-06-01
Series:	ESC Heart Failure
Subjects:	ICI, immune checkpoint inhibitor iRC, immune checkpoint inhibitor‐related cardiotoxicity Inflammatory biomarkers NER, neutrophil‐to‐eosinophil ratio
Online Access:	https://doi.org/10.1002/ehf2.14340

Similar Items

Clinical manifestation and management of immune checkpoint inhibitor‐associated cardiotoxicity
by: Xiaoxiao Guo, et al.
Published: (2020-02-01)

The Potential Cardiotoxicity of Immune Checkpoint Inhibitors
by: Inbar Nardi Agmon, et al.
Published: (2022-02-01)

Cardiotoxicity induced by immune checkpoint inhibitor: The complete insight into mechanisms, monitoring, diagnosis, and treatment
by: Sridha Ganesh, et al.
Published: (2022-09-01)

Immune Checkpoint Inhibitor-Associated Cardiotoxicity in Solid Tumors: Real-World Incidence, Risk Factors, and Prognostic Analysis
by: Xue Chen, et al.
Published: (2022-05-01)

Cardiotoxicity Induced by Immune Checkpoint Inhibitors: What a Cardio-Oncology Team Should Know and Do
by: Concetta Zito, et al.
Published: (2022-11-01)

The Association between a Decrease in On-Treatment Neutrophil-to-Eosinophil Ratio (NER) at Week 6 after Ipilimumab Plus Nivolumab Initiation and Improved Clinical Outcomes in Metastatic Renal Cell Carcinoma
by: Yu-Wei Chen, et al.
Published: (2022-08-01)

Cardiotoxicity associated with immune checkpoint inhibitors: Current status and future challenges
by: Lu Gan, et al.
Published: (2022-08-01)

Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment
by: Nicolas Palaskas, et al.
Published: (2020-01-01)

Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors
by: Moran Gvili Perelman, et al.
Published: (2024-01-01)

Immune Checkpoint Inhibitors Related to Cardiotoxicity
by: Ru Chen, et al.
Published: (2022-11-01)

Myocarditis associated with immune checkpoint inhibitors: Practical considerations in diagnosis and management
by: Muhammet Gürdoğan, et al.
Published: (2020-07-01)

Gender differences in cardiotoxicities associated with immune checkpoint inhibitor therapy in cancer patients
by: Sheharyar Minhas, et al.
Published: (2020-01-01)

Cardiotoxicity of checkpoint inhibitors: focus on immune side effects
by: Yuri I. Buziashvili, et al.
Published: (2024-04-01)

Advances in immune checkpoint inhibitors induced-cardiotoxicity
by: Xiang Li, et al.
Published: (2023-02-01)

Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies
by: Daniel Ronen, et al.
Published: (2022-03-01)

Immune Checkpoint Inhibitors—Associated Cardiotoxicity
by: Chenghui Li, et al.
Published: (2022-02-01)

Cardiotoxicity Secondary to Immune Checkpoint Inhibitors in the Elderly: Safety in Real-World Data
by: Irene Toribio-García, et al.
Published: (2023-08-01)

Cardiotoxicity Related to Immune Checkpoint Inhibitors: A Real-World Retrospective Analysis
by: Jianqing She, et al.
Published: (2022-05-01)

Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment
by: Zhifei Gao, et al.
Published: (2023-02-01)

Clinical Manifestations, Monitoring, and Prognosis: A Review of Cardiotoxicity After Antitumor Strategy
by: Wei Huang, et al.
Published: (2022-06-01)

Overview of the Cardiotoxicity Induced by PD-1/PD-L1 Immune Checkpoint Inhibitor in Critical Care
by: Ruiting Li, et al.
Published: (2021-06-01)

Evidences of CTLA-4 and PD-1 Blocking Agents-Induced Cardiotoxicity in Cellular and Preclinical Models
by: Vincenzo Quagliariello, et al.
Published: (2020-10-01)

Eosinophil accumulation predicts response to melanoma treatment with immune checkpoint inhibitors
by: Sonja C. S. Simon, et al.
Published: (2020-01-01)

Advance in Drug Resistance Mechanism of Immune Checkpoint Inhibitors
by: ZHANG Lanlan, et al.
Published: (2020-08-01)

Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlights
by: Randolph J. Noelle, et al.
Published: (2023-09-01)

Research Progress on Cardiotoxicity of PD-1/PD-L1 Immune Checkpoint Inhibitors
by: YU Lin, et al.
Published: (2021-08-01)

Cardiac toxicity in patients with lung cancer receiving thoracic radiotherapy and immunotherapy
by: Christine Son, et al.
Published: (2023-01-01)

ICIs-Related Cardiotoxicity in Different Types of Cancer
by: Mei Dong, et al.
Published: (2022-06-01)

Risk Factors, Incidence, and Prognosis of Thromboembolism in Cancer Patients Treated With Immune Checkpoint Inhibitors
by: Xue-lin Zou, et al.
Published: (2021-11-01)

Case Series of Steroid-Resistant Immune Checkpoint Inhibitor Associated Myocarditis: A Comparative Analysis of Corticosteroid and Tofacitinib Treatment
by: Cong Wang, et al.
Published: (2021-12-01)

Combining radiation with immune checkpoint inhibitors therapy for HCC: From the alteration of the immune microenvironment by radiotherapy
by: Kaixiao Zhou, et al.
Published: (2022-12-01)

NK Cell-Based Immune Checkpoint Inhibition
by: Muhammad Khan, et al.
Published: (2020-02-01)

Immune checkpoint inhibitor myocarditis: a systematic case study
by: E. A. Kushnareva, et al.
Published: (2020-12-01)

Circulating biomarkers in the diagnosis and prognosis of immune checkpoint inhibitor-related myocarditis: time for a risk-based approach
by: Gillian Murtagh, et al.
Published: (2024-02-01)

Characterization of Immune Checkpoint Inhibitor-Related Cardiotoxicity in Lung Cancer Patients From a Rural Setting
by: Melissa Y.Y. Moey, MD, MSc, et al.
Published: (2020-09-01)

Cardiotoxicity Induced by Immune Checkpoint Inhibitors: A Pharmacovigilance Study From 2014 to 2019 Based on FAERS
by: Chenxin Chen, et al.
Published: (2021-02-01)

Immune Checkpoint Inhibitor–Related Cardiovascular Toxicity in Lung Cancer
by: Lova Sun, MD, et al.
Published: (2019-12-01)

A practical prognostic peripheral blood-based risk model for the evaluation of the likelihood of a response and survival of metastatic cancer patients treated with immune checkpoint inhibitors
by: Satu Tiainen, et al.
Published: (2023-12-01)

Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis
by: Xinqing Lin, et al.
Published: (2022-01-01)

Corneal Transplant Rejections in Patients Receiving Immune Checkpoint Inhibitors
by: Majid Moshirfar, et al.
Published: (2022-09-01)